FierceBiotechOriginal article
{"a":[{"_":"Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped","$":{"href":"/biotech/novos-blockbuster-hopes-ckd-program-dwindle-after-more-phase-3-trials-scrapped","hreflang":"en"}}]}
Phase 3negativeziltivekimabNegative
AI Analysis
Summary
Novo Nordisk has discontinued two phase 3 trials of ziltivekimab for chronic kidney disease, significantly diminishing prospects for the molecule that was previously considered a potential blockbuster.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Two phase 3 trials scrapped
Importance:7/10
Sentiment:
-0.80
Phase 3 failureCKDclinical developmentprogram discontinuation
Related Companies
Read the original article
Published by FierceBiotech on September 7, 2026 8:40 AM